<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735290</url>
  </required_header>
  <id_info>
    <org_study_id>IM-202</org_study_id>
    <nct_id>NCT03735290</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer</brief_title>
  <acronym>ILIAD</acronym>
  <official_title>A Randomized, Open-label, Multi-center, Phase 1b/2 Trial Evaluating the Safety and Efficacy of Intratumorally-administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who Are Candidates for CPI Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunicum AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunicum AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing
      dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor
      (CPI) pembrolizumab. The Phase 1b study will determine the optimal dose and schedule of
      ilixadencel. Patients in the Phase 2 part of the study will be randomly assigned to receive
      either ilixadencel (at the dose determined in Phase 1b) combined with the CPI, or only the
      CPI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite improvements achieved with the use of CPIs, 50-80% of cancer patients do not respond
      to this therapy. There is growing evidence that combining CPIs with other forms of
      immunotherapy has the potential to improve the desired effects of both CPIs and
      immunotherapies. This study looks at the safety and effectiveness of the immunotherapy
      ilixadencel when used in combination with a CPI. A Dose-escalation Committee (DEC) will
      monitor the study for any significant safety issues during Phase 1b.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single arm phase 1b. Randomized phase 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs) (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events (SAEs) (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs) (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Dose Limiting Toxicities measured using CTCAE v5.0 and protocol DLT definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant laboratory test abnormalities (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with vital sign abnormalities (Phase 1b)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Vital signs grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor Objective Response Rate (ORR) (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, centrally assessed using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor Objective Response Rate (ORR) RECIST 1.1 (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, investigator and centrally assessed using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Objective Response Rate (ORR) iRECIST (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Antitumor activity of ilixadencel plus CPI (checkpoint inhibitor) in each tumor type, investigator assessed using iRECIST (Immune Response Evaluation Criteria in Solid Tumors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Rate of complete and partial response and stable disease by investigator and centrally assessed RECIST (Response Evaluation Criteria in Solid Tumors) v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of circulating CD8 t-cell responses to tumor-specific or tumor-associated antigens (Phase 1b and Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Measured by flow-cytometry analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 24 months after Cycle 1 Day 1</time_frame>
    <description>Measured in weeks. Assessed using RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 24 months after Cycle 1 Day 1</time_frame>
    <description>Measured in weeks. Assessed using RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 24 months after Cycle 1 Day 1</time_frame>
    <description>Measured in weeks. Centrally assessed using RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Phase 1b and Phase 2)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Measured in months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events (AEs) (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events (AEs) (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs) (Phase 2)</measure>
    <time_frame>Up to week 27</time_frame>
    <description>Dose Limiting Toxicities measured using CTCAE v5.0 and protocol DLT definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant laboratory test abnormalities (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with vital sign abnormalities (Phase 2)</measure>
    <time_frame>Up to Week 27</time_frame>
    <description>Vital signs grading per Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Squamous Cell of Head and Neck</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 1, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 2, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 3, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Cohort 4, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ilixadencel</intervention_name>
    <description>Intra-tumoral injection</description>
    <arm_group_label>Phase 1b: Cohort 1, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 2, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 3, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 4, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg</description>
    <arm_group_label>Phase 1b: Cohort 1, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 2, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 3, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 1b: Cohort 4, ilixadencel + pembrolizumab</arm_group_label>
    <arm_group_label>Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
    <arm_group_label>Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must provide written informed consent.

          -  Must have histologically confirmed and specific (Human Papilloma Virus) HPV-positive
             or HPV-negative squamous cell carcinoma of the head and neck (SCCHN), non-small-cell
             lung cancer (NSCLC) or gastric or gastroesophageal junction (GEJ) adenocarcinoma.
             Tumor histology and most recent pathology report must be in subject's medical record.
             Tumor samples and/or biopsies will not be collected as part of this study.

          -  Eligible for pembrolizumab treatment per country-specific label and per physician's
             decision.

          -  ECOG 0 or 1.

          -  Adequate organ function.

          -  Women of childbearing potential must follow contraceptive requirements; must have a
             negative pregnancy blood test at screening, and a negative blood or urine pregnancy
             test within 24 hours before each dose of ilixadencel; and must not be breastfeeding.

          -  Male subjects must agree to use condoms from screening until 90 days after the last
             dose of ilixadencel, or must have a female partner using a highly effective method of
             contraception as described above.

        Exclusion Criteria:

          -  Prior history of invasive malignancy, unless complete remission has been achieved for
             at least 3 years and no additional therapy is required except for hormonal therapy or
             bisphosphonates.

          -  Active or previously untreated brain and/or leptomeningeal metastasis.

          -  Active autoimmune disease, pneumonitis or interstitial lung disease.

          -  Certain heart conditions including, but not limited to: Congestive heart failure;
             uncontrolled hypertension; unstable angina pectoris; pericarditis; myocarditis;
             mycardial infarction 6 months prior to study.

          -  Systemic immunosuppression except for replacement therapy.

          -  Life expectancy of less than 3 months.

          -  Any prior treatment with ilixadencel or prior treatment with anticancer agents (except
             pembrolizumab or other CPI for subjects in Phase 1b) within 4 weeks of starting study
             medication.

          -  Major surgery or significant traumatic injury within 4 weeks before study start.

          -  Known infection with human immunodeficiency virus (HIV).

          -  Active tuberculosis; active infection with hepatitis B virus or hepatitis C virus;
             active infection requiring anti-infective therapy.

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Domeij, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Immunicum AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Campbell</last_name>
    <phone>+1 910-558-8815</phone>
    <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 1010</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please email ImmunicumClinicalTrial.sm@ppdi.com. First line of the email MUST contain NCT03735290 and Site #.</last_name>
      <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1006</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please email ImmunicumClinicalTrial.sm@ppdi.com. First line of the email MUST contain NCT 03735290 and Site #.</last_name>
      <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1011</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please email ImmunicumClinicalTrial.sm@ppdi.com. First line of the email MUST contain NCT 03735290 and Site #.</last_name>
      <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1001</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please email ImmunicumClinicalTrial.sm@ppdi.com. First line of the email MUST contain NCT 03735290 and Site #.</last_name>
      <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1004</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please email ImmunicumClinicalTrial.sm@ppdi.com. First line of the email must contain NCT 03735290 and Site #.</last_name>
      <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 1009</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please email ImmunicumClinicalTrial.sm@ppdi.com. First line of the email MUST contain NCT 03735290 and Site #.</last_name>
      <email>ImmunicumClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>ilixadencel</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>allogeneic</keyword>
  <keyword>somatic cell therapy</keyword>
  <keyword>dendritic cell</keyword>
  <keyword>intratumoral</keyword>
  <keyword>in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

